We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Immunodiagnostic Test Predicts Progression of Pancreatic Cyst to Cancer

By LabMedica International staff writers
Posted on 17 Jun 2019
By using an immunodiagnostic test to detect the Das-1 antibody biomarker in fluid from pancreatic cysts, researchers were able to identify those cysts that were likely to become cancerous with 95% accuracy.

Although pancreatic cystic lesions (PCLs) are frequently and incidentally detected, it has been difficult to determine their risk of malignancy. More...
Previous studies had indicated that in immunohistochemical and ELISA analyses of tissue and cyst fluid from pancreatic intraductal papillary mucinous neoplasms (IPMNs), the monoclonal antibody Das-1 identified those at risk for malignancy with high levels of specificity and sensitivity. Therefore, investigators at Washington University (St. Louis, MO, USA) used pancreatic cyst samples from a multicenter cohort to validate the ability of Das-1 to identify high-risk PCLs, in comparison to clinical guidelines and clinical features.

For this study, the investigators obtained cyst fluid samples of 169 PCLs (90 IPMNs, 43 mucinous cystic neoplasms, and 36 non-mucinous cysts) from patients undergoing surgery at four tertiary referral centers. Histology findings from surgical samples, analyzed independently and centrally re-reviewed in a blinded manner, were used as the reference standard. An ELISA with Das-1 was performed in parallel using banked cyst fluid samples.

The results of the analyses revealed that the ELISA for Das-1 identified high-risk PCLs with 88% sensitivity and 99% specificity, and 95% accuracy, at a cut-off optical density value of 0.104. In 10-fold cross validation analysis with 100 replications, Das-1 identified high-risk PCLs with 88% sensitivity and 98% specificity.

“Some cysts have the potential to become pancreatic cancer, so there is the thought that we should err on the side of caution and remove the cysts,” said first author Dr. Koushik K. Das, assistant professor of medicine at Washington University. “But pancreas surgery is complicated. It often requires removal of the spleen, portions of the stomach, small intestine, and bile duct. In an ideal world, we only would do surgery on people whose pancreatic cysts are likely to develop into cancer. As it is, we probably do not operate on some people who need surgery and sometimes do operate when cancer is not present because we are working with imprecise information. Many cysts, if not most, probably should be left alone. But we do that at our peril because we may miss individuals harboring cancer. If we had a better biomarker, we would not have to rely on imperfect clinical and radiographic information.”

The Das-1 ELISA study was published in the June 5, 2019, online edition of the journal Gastroenterology.

Related Links:
Washington University


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.